Elicio Therapeutics set its 2026 annual stockholder meeting for November 12 and established September 24 as the deadline for proposals, director nominations and certain proxy notices. The dates give investors a defined timetable for submitting matters for consideration and seeking inclusion in the company’s proxy materials.

Key Highlights

  • Elicio Therapeutics set its 2026 annual meeting for November 12, 2026.
  • Stockholder proposals under Rule 14a-8 must be received by September 24, 2026.
  • Bylaw notices for director nominations and other matters, along with required Rule 14a-19 notices, must be provided by September 24, 2026.

Elicio Therapeutics, Inc. (NASDAQ: ELTX) has set November 12, 2026, for its annual meeting of stockholders. The company will provide the meeting’s exact time, location and voting matters in its proxy statement.

September 24 Deadline Covers Proposals and Nominations

Stockholder proposals intended for inclusion in the proxy materials must reach Elicio Therapeutics by September 24, 2026. Proposals must comply with the company’s amended bylaws and applicable Securities and Exchange Commission requirements. Director nominations and other matters submitted under the bylaws must also arrive by September 24, 2026, for consideration at the annual meeting.